Accueil>>Signaling Pathways>> Microbiology & Virology>> HSV>>Tromantadine hydrochloride

Tromantadine hydrochloride

Catalog No.GC60373

Le chlorhydrate de tromantadine, un dérivé de l'amantadine À activité antiherpétique, inhibe la réplication du virus de l'herpès simplex de type 1 (HSV-1) et du HSV-2.

Products are for research use only. Not for human use. We do not sell to patients.

Tromantadine hydrochloride Chemical Structure

Cas No.: 41544-24-5

Taille Prix Stock Qté
5mg
324,00 $US
En stock
10mg
538,00 $US
En stock
50mg
1 530,00 $US
En stock
100mg
2 364,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tromantadine hydrochloride, an Amantadine derivative with antiherpetic activity, inhibits herpes simplex virus type 1 (HSV-1) and HSV-2 replication[1].

Treatment of the cells with 10 to 50μg of Tromantadine reduces HSV-induced cytopathic effect. Treatment with 100 to 500μg of Tromantadine inhibits herpes simplex virus-induced cytopathic effect and reduces virus production. Complete inhibition of virus production is observed with treatments of 500μg to 1 mg. The antiherpetic activity of Tromantadine is dependent upon the viral inoculum size and the time of addition of the compound with respect to infection[1].

[1]. Rosenthal KS, et al. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother. 1982 Dec;22(6):1031-6.

Avis

Review for Tromantadine hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tromantadine hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.